



ASX ANNOUNCEMENT

11 December 2018

Appointment of Chief Operating Officer, Chief Financial Officer and Company Secretary

Melbourne, Australia, 11 December 2018: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) is pleased to announce the appointment of Mr Paul Viney who will be joining the Company on December 27th 2018 as Chief Operating Officer, Chief Financial Officer and Company Secretary.

Paul was most recently at Powerhouse Ventures in New Zealand and has over 15 years’ experience in governance and strategic leadership of mid and small cap ASX listed entities, coupled with a strong mix of industrial (manufacturing) and med-tech company experiences and sound venture capital knowledge

He brings broad business acumen to the Company in addition to his strong foundation in finance, IT and corporate governance.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr Paul Kasian
Chairman & Interim CEO
Genetic Technologies Limited
+ 61 3 8412 7000

Jason Wong (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 4

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company embracing blockchain technologies across Genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen^{plus}[®], is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogencesciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the [Private Securities Litigation Reform Act](#). The Private Securities Litigation Reform Act



genetic technologies

of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.